sintilimab,IBI939
innovent biologics,eli lilly
['nsclc', 'sintilimab', 'sclc', '$ivbxf', 'innovent']
$ivbxf new article : innovent updates phase 1b data of ibi939 (anti-tigit monoclonal antibody) combined with sintilimab in previously untreated pd-l1-selected nsclc at the 2023 asco annual meeting 
Effortlessly track financial news and never miss an article again with https://t.co/hKE5DiO0B4. Our real-time database combines trusted financial news sources for easy access.